153 related articles for article (PubMed ID: 32534880)
21. Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs.
Chen C; Casale EJ; Duncan B; Culverhouse EH; Gilman J
Pharmacotherapy; 1999 Apr; 19(4):437-41. PubMed ID: 10212015
[TBL] [Abstract][Full Text] [Related]
22. Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage?
Morris RG; Black AB; Lam E; Westley IS
Ther Drug Monit; 2000 Dec; 22(6):656-60. PubMed ID: 11128232
[TBL] [Abstract][Full Text] [Related]
23. Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy.
Goa KL; Ross SR; Chrisp P
Drugs; 1993 Jul; 46(1):152-76. PubMed ID: 7691504
[TBL] [Abstract][Full Text] [Related]
24. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients.
Inoue K; Suzuki E; Yazawa R; Yamamoto Y; Takahashi T; Takahashi Y; Imai K; Koyama S; Inoue Y; Tsuji D; Hayashi H; Itoh K
Ther Drug Monit; 2014 Jun; 36(3):406-9. PubMed ID: 24365988
[TBL] [Abstract][Full Text] [Related]
25. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy.
Otoul C; De Smedt H; Stockis A
Epilepsia; 2007 Nov; 48(11):2111-5. PubMed ID: 17651416
[TBL] [Abstract][Full Text] [Related]
26. [Open study evaluating lamotrigine efficacy and safety in add-on treatment and consecutive monotherapy in adult patients with epilepsy resistant carbamazepine and valproate].
Jóźwiak S; Niedzielska K; Mańko E; Terczyński A
Neurol Neurochir Pol; 2000; 34(4):673-89. PubMed ID: 11105300
[TBL] [Abstract][Full Text] [Related]
27. Lamotrigine clinical pharmacokinetics.
Rambeck B; Wolf P
Clin Pharmacokinet; 1993 Dec; 25(6):433-43. PubMed ID: 8119045
[TBL] [Abstract][Full Text] [Related]
28. Effect of antiepileptic drug comedication on lamotrigine concentrations.
Lovrić M; Čajić I; Petelin Gadže Ž; Klarica Domjanović I; Božina N
Croat Med J; 2018 Feb; 59(1):13-19. PubMed ID: 29498493
[TBL] [Abstract][Full Text] [Related]
29. Open study evaluating lamotrigine efficacy and safety in add-on treatment and consecutive monotherapy in patients with carbamazepine- or valproate-resistant epilepsy.
Jozwiak S; Terczynski A
Seizure; 2000 Oct; 9(7):486-92. PubMed ID: 11034873
[TBL] [Abstract][Full Text] [Related]
30. Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy.
Lovrić M; Božina N; Hajnšek S; Kuzman MR; Sporiš D; Lalić Z; Božina T; Granić P
Ther Drug Monit; 2012 Oct; 34(5):518-25. PubMed ID: 22972536
[TBL] [Abstract][Full Text] [Related]
31. Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy.
Klarica Domjanović I; Lovrić M; Trkulja V; Petelin-Gadže Ž; Ganoci L; Čajić I; Božina N
Br J Clin Pharmacol; 2018 Sep; 84(9):2106-2119. PubMed ID: 29791014
[TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetics of lamotrigine.
Chan V; Morris RG; Ilett KF; Tett SE
Ther Drug Monit; 2001 Dec; 23(6):630-5. PubMed ID: 11802095
[TBL] [Abstract][Full Text] [Related]
33. Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.
Berg M; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Switzer RD; Privitera MD
JAMA Neurol; 2017 Aug; 74(8):919-926. PubMed ID: 28654954
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and tolerability of conversion to monotherapy with lamotrigine compared with valproate and carbamazepine in patients with epilepsy.
Fakhoury TA; Hammer AE; Vuong A; Messenheimer JA
Epilepsy Behav; 2004 Aug; 5(4):532-8. PubMed ID: 15256191
[TBL] [Abstract][Full Text] [Related]
35. Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy.
Jawad S; Yuen WC; Peck AW; Hamilton MJ; Oxley JR; Richens A
Epilepsy Res; 1987 May; 1(3):194-201. PubMed ID: 3504397
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy.
Biton V
Expert Opin Drug Metab Toxicol; 2006 Dec; 2(6):1009-18. PubMed ID: 17125413
[TBL] [Abstract][Full Text] [Related]
37. Influence of UGT2B7, UGT1A4 and ABCG2 Polymorphisms on the Pharmacokinetics and Therapeutic Efficacy of Lamotrigine in Patients with Epilepsy.
Yang J; Wang J; Ning L; Wu C; Liu Y; Xia J; Guan Y; Liu Q; Zheng J
Eur J Drug Metab Pharmacokinet; 2024 Jul; 49(4):437-447. PubMed ID: 38709450
[TBL] [Abstract][Full Text] [Related]
38. Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening.
Yukawa E; Honda T; Ohdo S; Higuchi S; Aoyama T
J Pharm Pharmacol; 1997 Aug; 49(8):751-6. PubMed ID: 9379350
[TBL] [Abstract][Full Text] [Related]
39. Adult experience with lamotrigine.
Willmore LJ; Messenheimer JA
J Child Neurol; 1997 Nov; 12 Suppl 1():S16-8. PubMed ID: 9429125
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.
Chhun S; Jullien V; Rey E; Dulac O; Chiron C; Pons G
Epilepsia; 2009 May; 50(5):1150-7. PubMed ID: 19175400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
